The Delayed-Release Combination of Doxylamine and Pyridoxine (Diclegis®/Diclectin®) for the Treatment of Nausea and Vomiting of Pregnancy
- First Online:
- Cite this article as:
- Madjunkova, S., Maltepe, C. & Koren, G. Pediatr Drugs (2014) 16: 199. doi:10.1007/s40272-014-0065-5
- 2.1k Downloads
Nausea and vomiting of pregnancy (NVP) affects up to 85 % of all pregnancies. Effective treatment can greatly improve a woman’s quality of life, reduce the risk for maternal and fetal complications, and reduce healthcare costs. Unfortunately, many women receive either no pharmacological treatment or are recommended therapies for which fetal safety and efficacy have not been established. First-line treatment of NVP, as recommended by several leading healthcare and professional organizations, is the combination of doxylamine and pyridoxine. This combination, formulated as a 10 mg/10 mg delayed-release tablet, was approved by the US Food and Drug Administration (FDA) for the treatment of NVP in April 2013 under the brand name Diclegis®, and has been on the Canadian market since 1979, currently under the brand name Diclectin®. The efficacy of Diclegis®/Diclectin® has been demonstrated in several clinical trials, and, more importantly, studies on more than 200,000 women exposed to doxylamine and pyridoxine in the first trimester of pregnancy have demonstrated no increased fetal risk for congenital malformations and other adverse pregnancy outcomes. The present review aims to present the scientific evidence on the effectiveness and fetal safety of Diclegis®/Diclectin® for the treatment of NVP to justify its use as first-line treatment for NVP.
1.1 Clinical Presentation of Nausea and Vomiting of Pregnancy (NVP)
Nausea and vomiting of pregnancy (NVP), the most prevalent medical condition in pregnancy, affects up to 85 % of pregnant women. The commonly used term “morning sickness” is misleading as the symptoms of NVP can occur throughout the day and/or night. In a study involving 160 pregnant women, 74 % reported NVP symptoms, of whom, only 1.8 % experienced “morning sickness”, whereas, 80 % experienced NVP throughout the day . Symptoms of NVP include nausea, gagging, retching and/or vomiting. Typically, symptoms of NVP appear between 4 and 9 weeks of pregnancy, and are usually most severe between 7 and 12 weeks of pregnancy. For the majority of pregnant women, symptoms subside between 12 and 16 weeks of pregnancy; however, for up to 15 % of women, symptoms continue up to 20 weeks gestation, and less than 10 % of women suffer throughout their entire pregnancy [2, 3].
The severity of NVP can range from mild to severe. The most severe form of NVP is known as hyperemesis gravidarum (HG), which affects up to 0.3–2 % of pregnant women. HG typically requires hospitalization because of severe and persistent nausea and vomiting, weight loss greater than 5 % of pre-pregnancy weight, dehydration, electrolyte imbalances, and nutritional deficiencies [2–5]. Women who have had NVP in a previous pregnancy are more likely to have recurrence of NVP in subsequent pregnancies with the severity of NVP typically increasing in subsequent pregnancies. A 2004 study demonstrated that initiating any antiemetic treatment prior to or on first day of symptoms effectively lessened the severity of symptoms and reduced the recurrence of HG in women who experienced NVP in a previous pregnancy . Because of the high recurrence rate of NVP symptoms (75–85 %), it is important for women to receive early treatment to reduce the severity of symptoms, with the aim of preventing the need for hospitalization and improving quality of life .
1.2 Etiology of NVP
Although there are several theories, the etiology of NVP is thought to be multi-factorial and still remains unknown. This contributes to the difficulty in management of the condition, as no single theory has been shown to be applicable to all women [2–4, 7]. The most common theory is that hormonal changes during the first trimester of pregnancy, specifically human chorionic gonadotropin hormone (hCG), estrogen and progesterone, contribute to NVP. Women with molar and multiple pregnancies have higher hCG levels and, often, worse symptoms of NVP [2, 8]. Other hormonal imbalances, such as thyroid disorders, are thought to be associated with NVP as well. For example, women with hyperthyroidism have been found to be more prone to experience more severe symptoms of NVP [4, 8, 9]. Nausea during the first trimester is also associated with gastric slow wave dysrhythmias which correlate closely with symptomatology . It has been shown that the intensity of nausea is significantly greater in pregnant women with gastric dysrhythmias than in those with normal electrogastrographic patterns [8, 11, 12]. Research also shows that women with either pre-existing gastrointestinal (GI) conditions or untreated GI conditions, such as constipation, acid reflux and heartburn, ulcerative colitis, Crohn’s disease, Celiac disease or irritable bowel syndrome, are susceptible to more intense symptoms of NVP [11–13]. Many studies, including a meta-analysis, have shown an association between Helicobacter pylori infection and HG and/or severe NVP [14–16].
Additional factors such as underlying psychiatric conditions, liver abnormalities, elevated cytokine levels, vitamin deficiencies (vitamin B6, B1, and K), as well as the evolutionary adaptation have been proposed as part of the etiology for NVP [4, 9, 17]. Other studies have demonstrated evidence for genetic contributions for NVP susceptibility, which include familial recurrence, carrying a female fetus, monozygotic twin pair correlation, and previous history of HG [2, 18, 19].
1.3 Impact of NVP
Many studies have demonstrated that NVP can negatively affect women’s quality of life and their overall well-being [3, 20, 21]. Feelings of frustration, helplessness, resentfulness, and depression are common, experienced by 55 % of women suffering from NVP [12, 22]. These feelings, in turn, negatively influence a woman’s social life and family, with approximately half of women reporting adverse effects on their marital relationships due to NVP . In fact, because of the substantial impact of NVP, some women have electively terminated their pregnancy. In a study of 3,201 pregnant women experiencing NVP, 108 terminated their pregnancy because of NVP, and an additional 413 women considered termination . In addition to the aforementioned physical and emotional consequences, NVP also has a significant financial impact on both individuals and society [24, 25]. A recently published study estimated the 2012 total economic burden from NVP in the USA to be US$1,778,473,782—60 % in direct costs and 40 % in indirect costs—with the average cost of US$1,827 to manage one woman with NVP .
On the other hand, several studies have suggested that the presence of NVP is a predictor of favorable pregnancy outcome. In fact, this condition may have a protective effect on pregnancy, as studies have shown lower rates of miscarriages, stillbirths, preterm births, and birth defects [3, 9, 26]. Furthermore, a study in 121 mother–child pairs found that women who experienced NVP gave birth to infants with higher neurodevelopment scores compared with women without NVP . However, for women with insufficiently managed severe NVP or HG, there is an increased risk for adverse pregnancy outcomes such as small for gestational age, low birth weight, preterm delivery and low 5-min Apgar score [28–30].
1.4 Management of NVP
Women with mild symptoms may find lifestyle and dietary modifications to be sufficient to manage NVP symptoms . Additionally, non-pharmacological interventions such as acupressure bands, acupuncture or ginger root powder capsules may be used; however, studies have demonstrated that the efficacy and safety vary [31, 32].
A large number of antiemetics have been proven effective for the treatment of nausea and vomiting associated with conditions such as chemotherapy-induced nausea and vomiting, motion sickness, GI conditions or cyclic vomiting . However, their use in pregnancy is marred by lack of sufficient data on effectiveness and fetal safety . The only drug approved and indicated for the treatment of NVP is the delayed-release formulation of 10 mg doxylamine succinate and 10 mg pyridoxine hydrochloride (HCl), as it has been shown to be both effective and safe [35–39]. This combination is currently available as Diclegis® in the USA and Diclectin® in Canada.
Several leading professional organizations, such as the American College of Obstetricians and Gynecologists (ACOG) , the American Professors of Gynecology and Obstetrics , and the Society of Obstetricians and Gynecologists of Canada , and also teratogen information services, such as the Motherisk Program and MothertoBaby (formerly known as Organization of Teratogen Information Services) , recommend Diclegis®/Diclectin® as first-line therapy for the treatment of NVP. This recommendation is based on the extensive fetal safety and efficacy data available for this medication. The purpose of this review is to present the scientific evidence on the pharmacology, effectiveness, and fetal safety of Diclegis®/Diclectin® as first-line treatment for NVP.
2 History of Doxylamine/Pyridoxine
This combination was first introduced in the USA as Bendectin® in 1956. Initially, Bendectin® was formulated as a delayed-release combination of 10 mg doxylamine succinate, 10 mg pyridoxine, and 10 mg dicyclomine HCl [35, 43]. However, in 1976, an eight-way study of doxylamine, pyridoxine HCl, and dicyclomine showed that dicyclomine had no independent antiemetic effect, and therefore, Bendectin® was reformulated to contain 10 mg doxylamine succinate and 10 mg pyridoxine HCl [44–46]. Bendectin® was the drug of choice for NVP in the USA and other parts of the world under different trade names: Diclectin® in Canada, Debendox® in the UK and Australia, Lenotan® in Germany and Switzerland as well as in other countries of Europe, South America and Africa. It was widely prescribed and used by over 33 million women worldwide between 1956 and 1983 . However, in 1983, Bendectin® was voluntarily removed from the American market by the manufacturer, Merrell Dow Pharmaceuticals, because of litigations and false allegations about teratogenic effects. The International Federation of Gynecology and Obstetrics described the removal of Bendectin® as “the worst example in history of women being denied medication without a cause” . At that time, Bendectin® was the most studied drug in pregnancy, as a large number of cohort and case–control studies, as well as two separate meta-analyses, had demonstrated that it did not increase the risk of birth defects [36, 37, 45]. Committees assembled by both the FDA and Health Canada supported these findings, stating that the drug combination of doxylamine succinate and pyridoxine HCl does not increase malformation risk [47, 48].
After the removal of Bendectin® from the American market, the rates of hospitalization for severe NVP more than doubled in American women [45, 49]. With continuous use of Diclectin® in Canada, however, the rates of hospitalization for NVP in Canada have been shown to be lower than in the USA [47, 49]. This powerful evidence produced ecological, population-based proof for the therapeutic effectiveness of Bendectin® . It also painfully demonstrated the risks of denying women safe and effective pharmacotherapy during pregnancy. Even though the combination of doxylamine and pyridoxine was not commercially available in the USA, it has been recommended by the ACOG as first-line therapy for the treatment of NVP since 2004 . Unfortunately, these recommendations have led to the use of over-the-counter (OTC) preparations containing doxylamine, which are not equivalent in efficacy or fetal safety to the delayed-release formulation of Diclegis®, as they contain more than 10 mg of doxylamine as well as other active and inactive ingredients. Similarly, compounding pharmacies have combined doxylamine and pyridoxine in an attempt to offer pregnant women with NVP a suitable treatment option; however, to our knowledge, the safety and efficacy of these preparations have not been studied or approved by any regulatory agency. Combining 25 mg or 12.5 (if the tablet is cut) of doxylamine + 10 mg pyridoxine is not equivalent in efficacy to a delayed-release formulation combining 10 mg doxylamine + 10 mg pyridoxine. Furthermore, the concerns regarding safety include the following facts that (1) women have to ensure that they purchase the correct OTC medication that only includes doxylamine as the active ingredient, (2) women have to ensure they cut the 25 mg tablet in half, (3) various excipients may be present in the OTC forms of doxylamine that may have not been studied for fetal safety, and (4) no other doxylamine-containing product has a Pregnancy Category A rating by the FDA.
3 Composition of Diclegis®/Diclectin®
Diclegis®/Diclectin® are round, white, film-coated, delayed-release tablets imprinted with the pink image of a pregnant woman to indicate that the tablet is for pregnant women [50, 51]. Diclegis®/Diclectin® is a combination of 10 mg doxylamine succinate (an antihistamine) and 10 mg pyridoxine HCl (vitamin B6). Doxylamine succinate and pyridoxine HCl provide independent anti-nauseant and antiemetic activity [52–54]. The unique characteristic of Diclegis®/Diclectin® tablets that allows it to control NVP symptoms is the delayed-release action, making it critical to use on a strict schedule, and not on an as-needed basis . The enteric coating ensures that the active ingredients are released in a pH-dependent manner along the gut and small intestine to provide sustained antiemetic and anti-nauseant relief. In contrast, OTC preparations containing doxylamine are not formulated to be delayed-release, and hence, would not be able to effectively control NVP symptoms in the same manner as Diclegis®/Diclectin®. The standard recommended dose of Diclegis®/Diclectin® is typically up to four tablets daily: two tablets at bedtime, one in the morning, and one in the mid-afternoon. This delayed-release formulation permits the antiemetic action to occur 4–6 h after ingestion; therefore, the bedtime dose would be effective in the early morning, the morning dose would be effective in the afternoon and the mid-afternoon dose would be effective in the evening, providing 24 h control of NVP symptoms [50, 51].
3.1 Doxylamine Succinate
Doxylamine is well absorbed from the GI tract, with peak plasma concentrations achieved within 2–3 h, and the therapeutic effects usually persist for 4–6 h. Doxylamine is biotransformed in the liver by N-dealkylation to its principal metabolites N-desmethyl and N, N-didesmethyl-doxylamine, which are excreted by the kidney . Importantly, the delayed-release formulation of Diclegis®/Diclectin® tablets has different pharmacokinetics, which will be discussed below.
3.2 Pyridoxine Hydrochloride
Pyridoxine HCl (Fig. 1b) is the usual form of vitamin B6 included in pharmaceutical products. Vitamin B6 is a collective name for pyridoxine, pyridoxal, and pyridoxamine, which are related natural compounds with similar biological properties .
Pyridoxine is readily absorbed from the GI tract, mainly in the jejunum. The drug is primarily metabolized in the liver to its four active metabolites pyridoxal, pyridoxal-5-phosphate (PLP), pyridoxamine, and pyridoxamine-5-phosphate. Following phosphorylation, its main metabolite, PLP, is released into the circulation and is highly protein bound. PLP is a cofactor in over 160 enzyme activities involved in a number of metabolic processes of amino acids, nucleic acids, unsaturated fatty acids, carbohydrates, glycogen, neurotransmitters, and porphyrin. The major metabolite 4-pyridoxic acid is inactive, and is excreted by the kidney [58–61].
4 Pharmacokinetics of Diclegis®/Diclectin®
The first study on the pharmacokinetics of Diclectin® was published in 2009, almost 50 years after the invention of the delayed-release combination of doxylamine/pyridoxine (Bendectin®) . The purpose of this study was to confirm the delayed-release properties of Diclectin®. This randomized, crossover, open-label study compared the pharmacokinetics of the parent drugs, doxylamine succinate and pyridoxine HCl, and certain metabolites, pyridoxal and PLP, after oral administration of Diclectin® tablets (2 × 10 mg/10 mg) to a reference combination of doxylamine succinate and pyridoxine HCl oral solution (20 mL × 10 mg/10 mL). The study included 18 healthy, non-pregnant women of childbearing age under fasting conditions. Diclectin® exhibited similar bioavailability to the oral solution. Mean peak plasma concentration (Cmax) levels were similar for both doxylamine and pyridoxine after administration of Diclectin® (90.4 ± 13.1 vs. 98.7 ± 18.1 ng/mL) and the oral solution (50.7 ± 31.0 vs. 96.5 ± 46.7 ng/mL). In contrast, mean time to peak plasma level (Tmax), reflecting the rate of absorption, was shown to be three times longer for doxylamine (6.10 ± 1.77 vs. 2.04 ± 0.85 h), six times longer for pyridoxine (3.81 ± 1.20 vs. 0.618 ± 0.179 h), four times longer for pyridoxal (4.84 ± 1.44 vs. 1.15 ± 0.26 h), and six times longer for total pyridoxine after administration of Diclectin® compared with the oral solution (P < 0.0001). Mean Tmax values for PLP after administration of Diclectin® and the oral solution were similar (8.59 ± 2.77 vs. 7.64 ± 3.88 h). Results from this study verified the delayed-release property of Diclectin®.
Another single-center, open-label study including 18 non-pregnant, non-lactating, premenopausal women was conducted to determine the pharmacokinetics of doxylamine succinate and pyridoxine HCl after administration of a single dose of Diclectin® (2 × 10 mg/10 mg) under fasting conditions . The mean plasma–concentration profiles of doxylamine succinate and PLP demonstrated large variability among participants; furthermore, twofold variability was observed in the systemic exposure to doxylamine and 6.5-fold for PLP based on the mean area under the curve (AUC0→∞). In this study, for doxylamine, the mean elimination half-life (T½) was calculated to be 11.7 h, and mean Cmax was 90 ng/mL. For PLP, mean T½ was 56 h, and mean Cmax was 42.9 ng/mL. This study also calculated the bioavailability of pyridoxine to be 100 % .
A recent study determined the effect of sex on the pharmacokinetics and bioequivalence (BE) of Diclectin® . This single-center, reference-replicate study calculated the pharmacokinetic parameters from 1 h pre-dose until 72 h post-dose in healthy males (n = 12) and non-pregnant females (n = 12) after oral administration of two tablets. After 21 days, drug dosing and blood sampling was re-conducted as stated above. Results from this study found that females had significantly larger AUC0–t for both doxylamine (P ≤ 0.05) and pyridoxine (P ≤ 0.05) compared with males. They also had higher Cmax for doxylamine (P ≤ 0.05). BE testing did not show BE between males and females. The authors concluded that these results may have implications for future BE studies using doxylamine/pyridoxine, and that this drug, for use exclusively in women, should be studied in women and not in men .
The only study on the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in pregnant women was recently published . This study combined data from two published studies to compare the pharmacokinetics of Diclectin® in 18 non-pregnant women of childbearing age with 50 women in the first trimester of pregnancy treated with Diclectin® for NVP [39, 62]. The two sets of data allowed comparison of steady-state trough concentrations of doxylamine and of PLP. No differences in the apparent clearance (CL) of doxylamine were found between women in their first trimester of pregnancy and non-pregnant women on day 4 (median = 196.7 vs. 249.5 mL/h/kg, respectively, P = 0.065), day 8 (median = 248.4 vs. 249.5 mL/h/kg, respectively, P = 0.82), and day 15 (median = 200.9 vs. 249.5 mL/h/kg, respectively, P = 0.55). There was no difference in the apparent CL of PLP on day 15 (median = 342.3 vs. 314.7 mL/h/kg, respectively, P = 0.92). The results demonstrated that there was no pregnancy-induced effect in the apparent CL of both doxylamine and PLP in women during the first trimester of pregnancy despite the existence of NVP. Their data also indicate that the trough steady-state concentrations in women suffering from mild and moderate forms of NVP are not different from those achieved among non-pregnant controls [39, 62, 65].
Studies on the pharmacokinetics and bioavailability of the delayed-release combination of doxylamine/pyridoxine (Diclegis®/Diclectin®)
Author and year
Nulman et al., 2009
Pharmacokinetics of Diclectin®
18 non-pregnant females
Doxylamine Cmax threefold longer with Diclectin® than with oral solution
Gill et al., 2011
Systemic bioavailability and pharmacokinetics of Diclectin® after single dose under fasting conditions
18 non-pregnant females
The systemic bioavailability of Diclectin® appears to be around 100 %
Koren et al., 2013
Effect of sex on pharmacokinetics and bioequivalence of Diclectin®
24 (12 males/12 females, non-pregnant)
Bioequivalence testing did not demonstrate bioequivalence betwen males and females. Females have significantly larger systemic exposure to both components of Diclectin® than males
Matok et al., 2013
Comparing the pharmacokinetics of Diclectin® in non-pregnant females and in the first trimester of pregnancy
50 females in first trimester of pregnancy compared with 18 non-pregnant females
In the first trimester of pregnancy, the pharmacokinetics of Diclectin® are similar to those of non-pregnant females
Rowland et al., 1989
Pharmacokinetics of doxylamine in pregnant primates
No pregnancy-induced changes in pharmacokinetics
The results obtained from these recent pharmacokinetic studies from Diclectin® in pregnant women confirm the results of a doxylamine pharmacokinetic study in pregnant primates from the late 1980s . This study examined differences in the pharmacokinetics of doxylamine among baboons, cynomolgus monkeys and rhesus monkeys, and evaluated whether pregnancy had any effect on its pharmacokinetics when compared with non-pregnant rhesus monkeys. The study also evaluated whether multiple dosing of doxylamine alters its pharmacokinetics. The monkeys were administered a dose of 7 mg/kg/day (ten times the maximum human dosage) from days 22 to 50 of pregnancy. The results showed that there were no significant differences in pharmacokinetics among the three groups, and from those of non-pregnant rhesus monkeys. The pharmacokinetics of doxylamine after multiple dosing (day 50) was shown to be similar to the pharmacokinetics after single-dose administration on day 22. The study concluded that there were no pregnancy-induced changes in the pharmacokinetics of the doxylamine/pyridoxine combination .
These observations are of substantial clinical importance, indicating that during the first trimester of pregnancy, the major changes in the volume of distribution, protein binding and CL rate seen in later pregnancy for many other drugs are not found to occur with doxylamine. Although care should be exercised to avoid over-interpreting data from doxylamine compared with other drugs, these findings suggest that pharmacokinetic studies in fecund, non-pregnant women may reflect doxylamine disposition characteristics during the first trimester of pregnancy.
5 Clinical Effectiveness of the Delayed-Release Combination of Doxylamine/Pyridoxine
The clinical effectiveness of the delayed-release combination of doxylamine and pyridoxine has been documented in several randomized, controlled trials as well as in open post-marketing studies using Bendectin®, Debendox®, and Diclectin®. Additionally, several placebo-controlled clinical trials have been published, the results of which will be reviewed here.
The findings of a double-blind, placebo-controlled trial of Bendectin® (10 mg doxylamine, 10 mg pyridoxine, and 10 mg dicyclomine) were reported in 1959 . The study groups consisted of 109 patients, 52 randomized to receive Bendectin® and 57 to placebo, showing a favorable response to the active drug preparation of 94 % compared with only 65 % for placebo (P < 0.001). Of the patients who received Bendectin®, 23 (44 %) experienced complete relief of nausea.
Another double-blind, placebo-controlled trial found that in 70.7 % (n = 41) of patients who received Debendox® (10 mg doxylamine, 10 mg pyridoxine, and 10 mg dicyclomine), improvement in NVP severity was noted, compared with 55 % (n = 40) in those receiving placebo (P < 0.05) .
In a subsequent randomized, double-blind trial, the same active drug combination Debendox® (10 mg doxylamine, 10 mg pyridoxine, and 10 mg dicyclomine) with 10 mg of extra pyridoxine, or placebo along with 10 mg of pyridoxine, was given to 56 pregnant women suffering from NVP during the first 10 weeks of pregnancy, in a crossover design . Differences in nausea severity were statistically significant (P < 0.001) when treatment with placebo in the first week was changed to the active drug in the second week. Similarly, significant superiority for the active treatment was noted with regard to the severity of retching (P < 0.05) and vomiting (P < 0.02).
Results from two placebo-controlled studies on the efficacy of all individual components of Bendectin® were evaluated by the manufacturer of the drug, Merrell Dow Pharmaceuticals. These results are also summarized in a review known as the Drug Effectiveness Study Implementation process, which was conducted by the National Academy of Sciences and the FDA . The first study compared the efficacy of doxylamine plus dicyclomine, doxylamine, dicyclomine and placebo for NVP treatment in 716 patients. These results demonstrated that doxylamine plus dicyclomine was more effective for NVP treatment than placebo, a finding that was attributed to doxylamine since dicyclomine was not significantly more effective than placebo. The other study evaluated the efficiency of all components of Bendectin®, including pyridoxine alone and in various possible combinations, compared with placebo in more than 2,300 women with NVP . The results confirmed that the efficacy of Bendectin® was greater than that of placebo but showed no antiemetic contribution from dicyclomine. Doxylamine was the major component that demonstrated clear effectiveness in NVP treatment, while pyridoxine had a clear effect on nausea but probably not vomiting [46, 70]. Following these studies, dicyclomine was removed from the formulation, and Bendectin® continued to be manufactured as a combination of doxylamine and pyridoxine only.
One of the limitations of all of the previous studies was their short duration, which did not permit evaluation of long-term effectiveness, which is important in view of the possibility of reduced patient compliance due to potential adverse effects such as sedation. A study was conducted in 149 women being counseled by the Motherisk NVP program in Toronto, Canada . Participants were advised to take two Diclectin® tablets at bedtime; if NVP symptoms became apparent in the afternoon despite the previous evening dose, they were advised to take an additional tablet in the morning. A fourth tablet was taken at noon by participants whose NVP symptoms occurred in the late afternoon or evening. The first interview was conducted after the onset of symptoms, at six to eight weeks gestation, and the second evaluation was at 20 weeks. During the first interview of 106 patients, 71 % reported an improvement in their NVP symptoms due to Diclectin® use, 23 % did not report improvement and 1 % reported worsening of their symptoms. By 20 weeks gestation, an additional 25 of the original cohort of patients started Diclectin® therapy; 21 (84 %) reported improvement, 3 (12 %) reported no change, and 1 (4 %) experienced a worsening of symptoms. These results are very similar to those reported in the double-blind trial above , suggesting that, in the clinical setting, Diclectin® does not lose efficacy over time. It also showed that of 11 women who increased their dosage before 20 weeks, all reported NVP symptom improvement .
A quantitative and qualitative overview of observational, controlled, and randomized, controlled trials for drug effectiveness for NVP was conducted. The authors analyzed the safety and efficacy of NVP treatments and concluded that antihistamines, including Diclectin® and Bendectin®, are both safe and effective for NVP treatment .
Results from a randomized, double-blind, multicenter, placebo-controlled trial evaluating the effectiveness of the Diclectin® in the treatment of pregnant women (7–14 weeks gestation) suffering from NVP were published in 2010 . Women were recruited in 2008–2009 from three university medical centers in the USA. Women received Diclectin® (n = 131) or placebo (n = 125) for 14 days. Symptoms of NVP were evaluated daily using the validated Pregnancy-Unique Quantification of Emesis (PUQE) scale . Diclectin® therapy resulted in a significantly larger improvement in symptoms of NVP compared with placebo (P = 0.006) . After the trial, 64 women (48.9 %) receiving Diclectin® asked to continue compassionate use of their medication, as compared with 41 placebo-treated women (32.8 %) (P = 0.009). The use of Diclectin® was not associated with an increased rate of any adverse events as compared with the placebo group .
Summary of the studies on clinical efficacy of the delayed-release combination of doxylamine/pyridoxine
Author and year
Number of subjects
Geiger et al., 1959
109 (52 Bendectin®; 57 placebo)
Improvement of NVP in 94 % in exposed group/65 % in placebo (P < 0.001)
McGuinness and Binns, 1971
81 (41 Debendox®; 40 placebo)
Improvement of NVP in 70.7 % in exposed group/55 % in placebo (P < 0.05)
Wheatley et al., 1977
Debendox® + 10 mg pyridoxine/placebo + 10 mg pyridoxine
Crossover, double-blind, placebo-controlled
Improvement in nausea (P < 0.001), severity of retching (P < 0.05), and vomiting (P < 0.02)
DESI, Bendectin 4-way study, 1972
Doxylamine and dicyclomine more effective than placebo
DESI, Bendectin 8-way study, 1975
Double-blind, placebo-controlled (various combinations of the ingredients with placebo)
Doxylamine most effective, dicyclomine no effect, pyridoxine effective for nausea but not vomiting
Bishai et al., 2000
149 (long-term effectiveness)
Improvement in NVP 71 % in first 6–10 gw, 84 % in 20 gw
Magee et al., 2002
Antiemetics including antihistamines/Diclectin®/Bendectin®
24 controlled studies on safety of antihistamines; 7 controlled studies on efficacy
Quantitative and qualitative overview of observational, controlled, and randomized, controlled trials
Antihistamines, Diclectin® and Bendectin® safe and effective
Koren et al., 2010
256 (131 Diclectin®, 125 placebo)
Randomized, double-blind, multicenter, placebo-controlled
Improvement of NVP symptoms in Diclectin® group (P < 0.006) compared to placebo group
Kutcher et al., 2003
Epidemiological multicenter USA data (birth defects, sales, hospitalization)
No teratogenic effect of Bendectin®, twofold increase in hospitalization for women with NVP with decreased sales of Bendectin
Neutel and Johansen, 1995
Two- to threefold increase of hospitalizations rate after removal of Bendectin®
6 Optimal NVP Treatment Using Diclegis®/Diclectin®
Summary of the studies on efficacy and characteristics of optimal treatment with the delayed-release combination of doxylamine/pyridoxine (Diclectin®)
Author and year
Boskovic et al., 2003
68 females (suboptimally treated with 2 tablets/day instead of 4 tablets/day)
Observational, prospective study (optimal dosing by body weight and severity of symptoms)
Significant improvement of nausea (P < 0.001), frequency of vomiting (P = 0.02), and PUQE scores (P < 0.001) with optimal dosing
Atanackovic et al., 2001
225 females (n = 123 used recommended dose 4 tablets/day; n = 102 used more than recommended dose > 4 tablets/day)
Observational, prospective study (adjustment by body weight and severity of symptoms)
Diclectin® can be given at doses higher than 4 tablets/day to normalize for body weight or optimize efficacy
Constantine et al., 2012
258 females (n = 131 Diclectin® group, n = 127 placebo group)
Multicenter, double-blind, randomized, controlled trial of Diclectin® vs. placebo
Adherence to Diclectin® is dependent on the number of tablets prescribed per day, and treatment duration and effectiveness
Maltepe and Koren, 2013
Diclectin® preemptive treatment
59 females (n = 30 preemptive group: initiation of Diclectin® before symptoms began; n = 29 control group: initiation of Diclectin® at the first sign of NVP)
Prospective, randomized, controlled trial
Preemptive therapy conferred a significant reduction in HG as compared with the previous pregnancy (P = 0.047). Significantly more women had their NVP resolved before giving birth (78.2 vs. 50 %) (P < 0.002) in preemptive group
Because of the unique pharmacokinetic profile of this drug, optimal dosing and timely use are very important in appropriate control of NVP symptoms. The rates of suboptimal use and effect of optimal dosing of Diclectin® as a measure of effectiveness of NVP treatment was evaluated . Patients were recruited from the Motherisk NVP Helpline, assessed for NVP severity using PUQE scores, and their Diclectin® doses were subsequently increased according to body weight and individual symptoms. Sixty-eight women were enrolled and completed the study. Most of the women (50/68) were receiving suboptimal doses of Diclectin® despite their moderate to severe NVP, defined by the PUQE scale. Following a correction of the dose to four tablets a day, there was a significant decrease in length of nausea (from 4 to 3 h, P < 0.001), frequency of vomiting (from mean 1.6 to 1.3 a day, P = 0.02), and overall PUQE score (from mean 7.5 to 6.1, P < 0.001). This study demonstrated that Diclectin® should be dosed according to body weight and severity of symptoms .
Another observational, prospective study showed the improved effectiveness of appropriate dosing of Diclectin® using more than four tablets per day based on the severity of NVP symptoms and adjustment for body weight. No increase in adverse events or adverse pregnancy outcomes for the higher than standard dose of Diclectin® were observed .
In a secondary a priori analysis of data from the multicenter, double-blind, randomized, controlled trial of Diclectin® versus placebo for the treatment of NVP, the authors aimed to identify the determinants of adherence to Diclectin® in 258 patients with NVP. There were no differences in adherence rates according to ethnicity, race, or the presence of adverse events . Gravidity, average number of prescribed tablets per day, site of enrollment, and change in NVP severity measured by the PUQE score were associated with adherence. In the multivariable analysis, average number of tablets per day, change in PUQE score, number of treatment days, and site of enrollment were significantly predictive of adherence, with the former being negatively correlated. The authors concluded that the adherence to Diclectin® is dependent on the number of tablets prescribed per day, and treatment duration and effectiveness .
A recent prospective, randomized, controlled trial compared the effectiveness of the preemptive use of Diclectin® in women who had experienced severe NVP and/or HG in their previous pregnancy to women with a similar previous experience who received Diclectin® only on the first sign of nausea, in addition to both groups receiving standardized counseling . A total of 30 women were randomized into the preemptive group (initiation of Diclectin® before symptoms began) and 29 into the control arm (initiation of Diclectin® at the first sign of NVP). The initial dose of Diclectin® was two tablets at bedtime and was gradually adjusted to NVP severity. Preemptive therapy conferred a significant reduction in HG as compared with the previous pregnancy (P = 0.047). In the preemptive arm, there were 2.5-fold fewer cases of moderate-severe cases of NVP than those in the control group (15.4 vs. 39.13 %) in the first 3 weeks of NVP (P = 0.05). In the preemptive group, significantly more women had their NVP resolved before giving birth (78.2 vs. 50 %) (P < 0.002). These results, although preliminary, demonstrate that preemptive treatment with Diclectin® may be beneficial in decreasing the risk for severe forms of NVP .
Because the delayed-release combination was not available in the USA for 30 years, even though it was recommended as first-line treatment for NVP, a common practice in the USA became recommending separate OTC preparations of doxylamine and vitamin B6 for NVP treatment. Although this therapy may, at most, yield short-lived relief of symptoms if women do not vomit the tablets before they are broken down and absorbed by the body, women will not benefit from the sustained therapeutic effect of the delayed-release form that has been demonstrated with the use of Diclegis®/Diclectin®. Moreover, doxylamine appears in numerous generic forms, under different names and dosages, and to our knowledge, not a single study has been published to demonstrate the safety and efficacy of these forms for treatment of NVP. It is important to note that the fetal safety of Diclegis®/Diclectin® has been well-established; however, other doxylamine-containing products have not received a FDA Pregnancy Category A rating and are not indicated for use in pregnancy. In order to ensure safe and effective therapy for NVP, Diclegis®/Diclectin® use should be first-line.
7 Fetal Safety of the Delayed-Release Combination of Doxylamine/Pyridoxine
As previously stated, the fetal safety of no other drug has been as extensively studied as the delayed-release combination of doxylamine and pyridoxine. Bendectin® was the most frequently prescribed antiemetic for the treatment of nausea and vomiting between 1956 and 1983, with an estimated 33 million exposures . According to several studies, up to 40 % of women took the drug during their first trimester of pregnancy in the late 1970s and early 1980s. In 1969, allegations questioning Bendectin's safety were raised. While these were individual case reports that did not specify patients’ past medical history, scores of similar cases were brought to court in the following years with claims of teratogenicity [43, 47]. As a result of escalating legal costs, the manufacturer decided to remove the drug from the market in 1983 [35, 78]. This decision was made despite the fact that a convincing body of scientific evidence had documented the safety of this product in pregnancy, including an expert panel convened by the FDA that unequivocally refuted the claims of teratogenicity .
Teratogenicity studies of the ingredients of Diclectin® in multiples of the maximal human dose (MHD) administered during the respective periods of organogenesis performed in rats (90× MHD), rabbits (up to 125× MHD), mice (up to 60× MHD), and monkeys (10–20× MHD) showed no consistent pattern of abnormalities following fetal exposure [35, 80, 81].
To address the question of potential teratogenicity of Bendectin® in humans, two separate meta-analyses were conducted which combined all controlled studies of pregnancy outcome following the use of this product during the first trimester. Both studies failed to show an overall increase in malformation rates, or in specific malformations. A systematic analysis of data from 12 cohort and five case–control studies totaling close to 200,000 patients calculated the overall summary odds ratio to be 1.01, indicating the absence of any increased risk, with a 95 % confidence interval (CI) of 0.66–1.55. When the two types of studies were separated according to their design, the summary odds ratio was 0.95 (95 % CI 0.62–1.45) for cohort studies, and 1.27 (95 % CI 0.83–1.94) for case–control studies .
A second meta-analysis was conducted combining data from 16 cohort and 11 case–control studies . The pooled estimate of the relative risk for any malformation at birth in association with exposure to Bendectin® in the first trimester was 0.95 (95 % CI 0.88–1.04). Separate analyses for cardiac defects, limb defects, oral clefts, and genital tract malformations yielded pooled estimates of relative risk ranging from 0.81 for oral clefts to 1.11 for limb defects, with no differences between Bendectin® and the controls. As a group, these studies have shown no differences in the risk of birth defects between those infants whose mothers had taken Bendectin® during the first trimester of pregnancy and those who had not .
An observational, prospective study was conducted in Canada with the objective to determine the incidence of adverse maternal and fetal effects and pregnancy outcome in 225 women taking Diclectin® at the recommended (1–4 tablets) (n = 123) or higher than recommended (5–12 tablets) (n = 102) doses. The results showed that higher than standard dose of Diclectin®, when calculated per kilogram of body weight, did not affect either the incidence of maternal adverse effects or adverse pregnancy outcomes .
In addition to the safety data on malformations and other adverse pregnancy outcomes, Diclegis®/Diclectin® is one of the few drugs that has safety information on the neurodevelopment of children exposed in utero. An observational cohort study of mother–child pairs was conducted to determine the effects of NVP and its treatment with Diclectin® on child neurodevelopment . The mother–child pairs were ascertained through the Motherisk NVP Helpline. Three groups of children were studied: 45 born to mothers who had NVP and were exposed to Diclectin®, 47 with mothers who had NVP but no Diclectin® exposure, and 29 born to mothers without NVP. Information on pregnancy, birth and early child development was ascertained through phone calls to mothers during pregnancy and 6–9 months after childbirth. A comprehensive set of psychological tests was conducted in children aged 3–7 years, and mothers were assessed for IQ and socioeconomic status. The results showed that Diclectin® does not appear to adversely affect fetal brain development and can safely be used to treat NVP .
Summary of the studies on fetal safety of the delayed-release combination of doxylamine/pyridoxine
Author and year
Einarson et al., 1988
Fetal safety of Bendectin®
Bendectin® exposed n = 14,715; n = 115,544 not exposed to Bendectin®
Meta-analysis, systematic analysis of data from 12 cohort and 5 case–control studies
Overall summary OR 1.01 (95 % CI 0.66–1.55). OR 0.95 (95 % CI 0.62–1.45) for cohort studies, and 1.27 (95 % CI 0.83–1.94) for case–control studies
McKeigue et al., 1994
Fetal safety of Bendectin®
Bendectin® exposed n = 18,055; controls n = 150,714, not exposed to Bendectin®
Meta-analysis, systematic analysis of data from 16 cohort and 11 case–control studies
RR for any malformation at birth in association with exposure to Bendectin® in the first trimester was 0.95 (95 % CI 0.88–1.04); pooled estimates of RR ranging from 0.81 for oral clefts to 1.11 for limb defects, with no differences between Bendectin® and the controls
Atanackovic et al., 2001
Fetal and maternal safety of Diclectin®
225 (n = 123 used recommended dose (1–4 tablets); n = 102 used more than recommended dose (5–12 tablets)
Observational, prospective study (adjustment by body weight and severity of symptoms)
Diclectin® given at doses higher than 4 tablets/day when calculated per kilogram of body weight did not affect either the incidence of maternal adverse effects or adverse pregnancy outcomes
Nulman et al., 2009
Safety information on neurodevelopment after exposure to Diclectin®
45 children born to mothers who had NVP and were exposed to Diclectin®, 47 children with mothers who had NVP but no Diclectin® exposure, and 29 children born to mothers without NVP
Observational, cohort study of mother–child pairs
Diclectin® does not adversely affect fetal brain development and can safely be used to treat NVP
In 1989, a report on the safety of the drug combination of pyridoxine/doxylamine for use in the management of NVP was prepared by a panel of Canadian and American experts for the Special Advisory Committee on Reproductive Physiology to the Health Protection Branch of Health Canada (currently called the Health Products and Food Branch) . These scientific experts concluded that “numerous studies in animals and in humans that have been reported in the scientific and medical literature demonstrate that Bendectin is not a teratogen…The safety of Bendectin®/Diclectin® in the management of nausea and vomiting of pregnancy has been established by its use in many thousands of pregnant women” .
The most reputable teratogen reference guides conclude that Diclegis®/Diclectin® is not associated with an increased risk for adverse pregnancy outcomes [82, 83]. Because of the extensive fetal safety data that exist, Diclegis® received a FDA Pregnancy Category A classification, indicating that adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy and there is no evidence of risk in later trimesters .
NVP remains a significant public health issue, and has negative physical, emotional, and financial consequences. Optimal treatment of this condition is warranted, and, to-date, the only approved medication indicated for the treatment of NVP is Diclegis®/Diclectin®. Furthermore, this drug has been recommended as first-line therapy for NVP treatment since the 1990s by leading professional organizations.
There is wide consensus that the Diclegis®/Diclectin® formulation is one of the best-studied drugs of all time for use in pregnancy, and that the great preponderance of evidence clearly confirms its documented effectiveness and safety profile. It is highly improbable that any other drug used for the treatment of NVP will ever be able to achieve the same degree of statistical power confirming the absence of a potential rare teratogenic effect. Similarly, individual components of doxylamine and pyridoxine available OTC are not able to control NVP symptoms as effectively as the delayed-release combination of Diclegis®/Diclectin®, and do not possess the same fetal safety and efficacy data. As a result, their use should not be encouraged by healthcare providers.
Diclegis®/Diclectin® is the only safe and effective treatment for a pregnancy-related condition suffered by many millions of women. Wider re-introduction of Diclegis®/Diclectin® in other countries is necessary to give pregnant women worldwide the same safe and effective option for NVP—for which they have been orphaned from—that is available in Canada and the USA.
Gideon Koren MD, FRCPC, FACMT, has served as a paid consultant for Duchesnay Inc., Blainville, Quebec and Bayer Inc, Germany. Dr. Koren received research grant support from Duchesnay Inc., Blainville, Quebec. The Motherisk Program is supported by Duchesnay Inc., Blainville, Quebec.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.